Pfizer's Hospital Business Acquires Arixa Pharmaceuticals

Pfizer Acquires Amplyx Pharmaceuticals

April 28, 2021

Biotechnology

Pfizer Inc. acquired Amplyx Pharmaceuticals, a privately held clinical-stage biotechnology company developing the antifungal candidate fosmanogepix (APX001). The deal expands Pfizer's anti-infectives pipeline and secures Amplyx's lead and early-stage assets to advance development of novel antifungal and antiviral therapies.

AmerisourceBergen Acquires PharmaLex from AUCTUS in €1.28bn Transaction

December 31, 2022

Healthcare Services

AmerisourceBergen Corporation acquired a majority stake in PharmaLex from funds advised by AUCTUS Capital Partners AG in a transaction that closed at year-end 2022 for approximately EUR 1.28 billion. PharmaLex, a Germany-headquartered provider of regulatory, clinical development and pharmacovigilance services to the life sciences industry, was grown under AUCTUS through a buy-and-build program of 38 add-ons and will expand AmerisourceBergen's global pharmaceutical solutions.

Alexion Pharmaceuticals Acquires Portola Pharmaceuticals

May 5, 2020

Biotechnology

Alexion Pharmaceuticals agreed to acquire Portola Pharmaceuticals in a cash tender offer at $18.00 per share to add Portola’s Factor Xa inhibitor reversal agent Andexxa and diversify Alexion’s commercial portfolio beyond its complement franchise. The transaction, unanimously approved by both boards, was expected to close in the third quarter of 2020 and will be funded with Alexion’s cash on hand.

APNAR Pharma Acquires Aurex Laboratories

February 3, 2022

Pharmaceuticals

APNAR Pharma LP, a privately owned pharmaceutical company based in Chino, California, has acquired East Windsor, New Jersey–based Aurex Laboratories. The deal adds US FDA–approved finished dosage manufacturing capabilities to APNAR’s platform, expanding its U.S. footprint, pipeline capacity and contract manufacturing capabilities to support APNAR’s ANDAs and third‑party partners.

Arxada Combines with Troy Corporation

November 3, 2021

Manufacturing

Arxada, the private-equity-backed specialty chemicals company owned by Bain Capital and Cinven, has entered into an agreement to combine with Troy Corporation. The deal will fold Troy's microbial-control and performance-additives capabilities and production footprint (including sites in the US, Germany, the Netherlands and Thailand) into Arxada, accelerating product innovation and expanding geographic and manufacturing reach.

Aditxt Inc. Signs Share Exchange Agreement to Acquire AiPharma Global Holdings LLC

December 28, 2021

Biotechnology

Aditxt Inc. (Nasdaq: ADTX) signed a share exchange agreement to acquire AiPharma Global Holdings LLC, a wholly owned subsidiary of AiPharma Group Ltd., in a two-step transaction that initially transfers a 9.5% interest followed by the remaining 90.5% subject to closing conditions and shareholder/Nasdaq approvals. The deal would give Aditxt commercial presence in infectious disease therapeutics and access to AiPharma's rights to Avigan (favipiravir) and related antiviral assets and distribution networks.